Skip to main
ATOS

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc. is highlighted as a promising investment due to its focus on developing proprietary treatments for significant medical needs in oncology and COVID-19, specifically through its lead drug, Endoxifen, as well as therapies AT-H201 and AT-301. The company's current valuation is considered attractive, with recent adjustments indicating a bullish outlook, signifying an increase in estimated value based on net present value (NPV) analyses. Moreover, the anticipated achievement of key clinical milestones and positive data is expected to serve as strong catalysts for the stock's performance moving forward.

Bears say

Atossa Therapeutics reported a net loss of $8.7 million for the period, reflecting a consistent earnings per share of $(0.07), which aligns with prior results but falls short of consensus estimates, highlighting a trend of persistent losses. The company faces significant risks, including balance sheet and liquidity challenges, potential failures of its drug candidates in clinical trials, and difficulties in gaining regulatory approval and commercialization. These factors, combined with competitive pressures and fluctuating investor sentiment in the biotech sector, contribute to a negative outlook for Atossa Therapeutics's stock.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.